Drug Safety : ADR Category 2
Disease-modifying antirheumatics/Nonsteroidal anti-inflammatories/Pamidronic acid
Lack of efficacy in critical conditions: 80 case reports Release Date: 16 Dec 2025 Update Date: 16 Dec 2025
Price :
$20
*